Media

Functional Renal Imaging and Advances in Kidney Cancer Detection - Shankar Siva

Details
Phillip Koo interviews Shankar Siva about advancements in functional renal imaging. Dr. Siva discusses the current standard imaging for localized kidney cancer, which includes triple-phase CT or MRI with IV contrast, and the limitations of bone scans for detecting metastases. He highlights the potential of sestamibi scanning for identifying benign kidney conditions and the promising results from t...

Navigating the Landscape of FDA-Approved PSMA Diagnostics: Pros and Cons - Delphine Chen

Details
Delphine Chen discusses the evolving landscape of PSMA diagnostics and therapies for prostate cancer with Phillip Koo. Dr. Chen outlines the use and performance of key PSMA imaging agents: Gallium-68 PSMA-11, and the F-18 agents PYLARIFY and POSLUMA. She explains how Gallium-68 PSMA-11, traditionally paired with Lutetium-177 PSMA, is effective but newer F-18 agents offer higher signal-to-noise rat...

COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection - Phillip Koo

Details
Zachary Klaassen and Phillip Koo discuss the results from the COBRA study, focusing on the innovative 64Cu-SAR-bisPSMA PET imaging presented at ASCO 2024. Dr. Koo explains that this new imaging agent has unique dual binding sites and advanced chelator technology, enhancing its attachment to prostate cancer cells and increasing the detection rate. The COBRA trial reveals that imaging performed the...

Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman

Details
Alicia Morgans discusses advances in prostate cancer imaging and theranostics with Michael Hofman. Dr. Hofman emphasizes the growing variety of PSMA ligands for PET-CT imaging and treatment, comparing their subtle differences and implications for clinical practice. He notes that while ligands like Gallium PSMA-11 and DCFPyL are similar and FDA-approved, others like PSMA-1007, although widely used...

COBRA Trial Shows Promise for 64Cu-SAR-bisPSMA PET in Biochemical Recurrence - Neal Shore

Details
Phillip Koo and Neal Shore discuss the COBRA trial, which investigates the use of 64Cu-SAR-bisPSMA PET imaging in prostate cancer patients with biochemical recurrence (BCR). Dr. Shore, the lead principal investigator, introduces Clarity, an Australian company developing Copper-64-based radiopharmaceuticals. He explains the advantages of Copper-64, such as its long half-life and bivalent structure,...

INDICATE Trial Seeks to Clarify Role of PET Scans in Prostate Cancer Recurrence - Neha Vapiwala

Details
Alicia Morgans interviews Neha Vapiwala about the innovative phase three INDICATE trial, supported by the ECOG-ACRIN Group and NCI designated cooperative groups. The trial focuses on patients with biochemical recurrence after prostatectomy, examining the impact of PET scans on treatment decisions. It categorizes patients based on PET scan results: those without detectable cancer outside the pelvis...

The 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer - Faina Shtern

Details
Phillip Koo converses with Faina Shtern who highlights that this year's Summit aims to bridge the significant gaps between the imaging community and clinical community. She emphasizes the future of prostate cancer diagnosis and treatment lies in the integration of multiple diagnostic methods such as MRI, molecular imaging, and genomic profiling. The 2023 Summit will introduce a multiomics panel fo...

PSMA PET's Influence on Prostate Cancer Studies - Jeremie Calais

Details
Phillip Koo talks with Jeremie Calais about the EMBARK trial and the impact of PSMA PET on patient population characterization. The discussion explores how the EMBARK trial began back in 2015 before the existence of PSMA PET and how its introduction has affected the understanding and definition of patient populations in prostate cancer studies. Calais explains how their team retrospectively looked...

Setting a Global Standard: Unveiling the New PSMA PET/CT Procedure Guideline - Wolfgang Fendler & Ken Herrmann

Details
Philip Koo discusses the newly updated PSMA PET/CT: Joint EANM, SNMMI procedure guideline, version 2.0, with its first and senior authors, Wolfgang Fendler and Ken Herrmann from Germany. The updated guideline, considered a landmark paper, integrates new ligands and types of imaging, consolidating information on PSMA imaging for different ligands and formalizing them as a class of ligands. It featu...

Tackling the Last Mile: A Major Component to Successfully Establish Radioligand Therapy - Ken Herrmann

Details
Phillip Koo welcomes Ken Herrmann to discuss Herrmann’s team's latest article, "Tackling the Last Mile: A Major Component to Successfully Established Radioligand Therapy," arguing the importance of 'the last mile' of treatment delivery in nuclear medicine. Drawing parallels with the logistics industry, Herrmann emphasizes the need for flawless delivery of therapy to patients, with patient awarenes...